NCT06401512

Brief Summary

Chronic Obstructive Pulmonary Disease (COPD), characterized by non-reversible airflow obstruction, contributes to high mortality and morbidity rates worldwide, including Norway. Individuals with COPD experience symptoms and complications that impede daily activities and diminish their quality of life. COPD places a growing burden on healthcare systems presently and in the future. Interventions to empower individuals to self-manage their health effectively are needed to help the challenges of living with COPD, and work towards a sustainable healthcare system. As part of the broader healthcare policy agenda, this project aligns with the increasing emphasis on digital homebased primary healthcare. The intervention in this study will combine digital homebased care and guided self-determination follow-ups (GSD) within a general practice setting. This project consists of 1) explore the feasibility of a COPD specific GSD counselling program delivered within a digital platform in primary care, 2) explore patients' and nurses' experiences applying the program, 3) examine the treatment fidelity of the intervention amongst healthcare professionals. This project is a pilot cluster-randomized controlled trial (RCT), including individuals diagnosed with COPD, conducted in primary healthcare settings, and assessment of feasibility and uncertainties before conducting a later full-scale cluster-RCT. The intervention draws upon the Medical Research Council's revised guidelines for developing complex intervention studies, focusing on the initial phases of intervention development and pilot testing. Primary care clinics are randomly assigned into either an intervention- or a control group. The intervention consists of the GSD counselling program with follow-up within a digital platform. The control group provide regular care. The project will include both qualitative (individual semi-structured interviews), and quantitative data (questionnaires and clinical data). In conclusion, this project explores an innovative intervention offering personalized strategies for COPD management in primary care clinic, by containing a digitalized homebased care program and follow-ups. The study aims to improve the daily living for people with COPD, while contributing to the future sustainability of healthcare systems.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
6mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
May 2024Dec 2026

First Submitted

Initial submission to the registry

April 23, 2024

Completed
9 days until next milestone

Study Start

First participant enrolled

May 2, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 6, 2024

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

January 23, 2025

Status Verified

January 1, 2025

Enrollment Period

2.6 years

First QC Date

April 23, 2024

Last Update Submit

January 20, 2025

Conditions

Keywords

COPDGuided self-determinationPrimary healthcareRandomized controlled trialWeb-based follow-up

Outcome Measures

Primary Outcomes (19)

  • Medical journal

    COPD-related information from medical journal

    Baseline, and 3, 6, 9 and 12 months

  • Qualitative data

    Individual interviews with participants

    6 - 18 months from baseline

  • Questionnaire

    Health literacy using the Health Literacy Questionnaire (HLQ).

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Impact of COPD using the COPD assessment test (CAT).

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Activity-level using International Physical Activity Questionnaire (IPAQ) - Short Form.

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Exacerbation-related information from patient

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Patient education and self-management using The Health Education Impact Questionnaire (HeiQ)

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Medication adherence using The My Experience of Taking Medicines Questionnaire (MyMEDS), adapted patients with COPD.

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Well-being using Well-Being Index (WHO-5).

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Self-rated health using EuroQol-5D-5L.

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Dyspnea using Dyspnea-12 questionnaire.

    Baseline, and 3, 6, 9 and 12 months

  • Questionnaire

    Patient satisfaction using Client Satisfaction Questionnaire (CSQ-8) and Patient global impression of change.

    Baseline, and 3, 6, 9 and 12 months

  • Weight

    Weight in kg

    Baseline and 12 months

  • Height

    Height in cm

    Baseline and 12 months

  • Recruitment rate for primary care practices

    Recruitment for primary care practices will be reported in terms of the number and proportion of primary care practices approached versus the practices that responded and, thereafter, the number who agreed to participate.

    Baseline

  • Recruitment rate for participants

    Participant recruitment will be reported in terms of the number of participants screened, found eligible, contacted, and those who provided written consent. Data for each recruitment step will be collected from all involved practices through self-reported numbers and the signed consent forms. Proportions will also be calculated for the number of participants screened versus those contacted, as well as for those contacted versus those who provided written consent.

    Baseline

  • Retention rate

    Retention will be reported as the number and proportion of participants who remain in the program at a certain timepoint. This will be calculated as the number of participants remaining in the program at each time point versus the number at baseline. To measure the retention rate, data from nurse reports, checklists, and medical records will be utilized.

    Baseline, and 3, 6, 9 and 12 months

  • Attrition rate

    The attrition rate, defined as the number of participants lost to follow-up, will be calculated as 1 minus the retention rate and as the number of participants lost to follow-up between consecutive time points. To measure the attrition rate, data from nurse reports, checklists, and medical records will be utilized. Additionally, data on who exited the program at what step and from whom we lack follow-up data will be collected.

    Baseline, and 3, 6, 9 and 12 months

  • Adherence rate

    Adherence rate will be collected in terms of number of sessions attended by each participant. To measure the adherence rate checklists and medical journals filled out by nurses conducting the intervention and self-reported data will be used.

    Baseline, and 3, 6, and 9 months.

Study Arms (2)

Intervention group

EXPERIMENTAL
Behavioral: Guided self-determination (GSD) follow-up approach by primary care nurses.

Control group

NO INTERVENTION

Regular follow-up by primary care physician.

Interventions

The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.

Intervention group

Eligibility Criteria

Age35 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with COPD living at home
  • Post-bronchodilator forced expiratory volume 1 s (FEV1) to forced vital capacity (FVC) below lower limit of normality

You may not qualify if:

  • Severe somatic disease
  • Severe psychiatric diagnosis
  • Not able to provide informed consent
  • Do not write, speak or understand Norwegian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Western Norway University of Applied Sciences

Bergen, Norway, 5063, Norway

RECRUITING

Related Publications (1)

  • Kolltveit BH, Graue M, Borge CR, Frisk B. Patients' experiences with participating in a team-based person-centred intervention for patients at risk of or diagnosed with COPD in general practice. Pilot Feasibility Stud. 2023 Sep 25;9(1):164. doi: 10.1186/s40814-023-01398-9.

    PMID: 37749601BACKGROUND

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Beate-Christin H Kolltveit, Ph.D.

    Western Norway University of Applied Sciences

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Beate-Christin H Kolltveit, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
The intervention is designed to evaluate a change in health service provision; therefore blinding of the intervention is not possible. The health care professionals, patients, and researchers were not blinded to the patients' group allocation. The statistician performing the analysis will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 23, 2024

First Posted

May 6, 2024

Study Start

May 2, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

January 23, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will share

All IPD collected throughout the trial.

Time Frame
Data will be available two years after publication.
Access Criteria
In accordance with the approvals granted for this study by the Regional Committee on Medical Research Ethics and the Norwegian Data Inspectorate, the data files will be stored securely and in accordance with the Norwegian Law of Privacy Protection. A subset of the data file with anonymized data will be made available to interested researchers upon reasonable request to Beate-Christin Hope Kolltveit: beate-christin.hope.kolltveit@hvl.no, providing that Norwegian privacy legislation and the General Data Protection Regulation are respected, and that permission is granted from the Norwegian Data Inspectorate and the data protection officer at Western Norway University of Applied Sciences.

Locations